I am more perplexed that FTO inhibition was not the cause for the synergy with Bisantrene/Decitabine in AML. Is the downstream target pathway actually mTor or did I miss something?
mTor is also a powerful pathway for autophagy drives cancer and inflammation. Perhaps Bisantrene also inhibits mTor independently from FTO that could be a beneficial from anti cancer and cardio protection?…
Ann: Bisantrene shows potent anticancer activity in AML models, page-81
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.62 |
Change
0.045(2.87%) |
Mkt cap ! $269.7M | |||
| Open | High | Low | Value | Volume |
| $1.58 | $1.62 | $1.58 | $139.9K | 86.98K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2000 | $1.62 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.63 | 100 | 1 |
View Market Depth
| Last trade - 12.59pm 06/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.66 |
Change
0.045 ( 5.77 %) |
||||
| Open | High | Low | Volume | ||
| $1.60 | $1.66 | $1.58 | 5136 | ||
| Last updated 13.11pm 06/06/2024 ? | |||||
| RAC (ASX) Chart |